Biotech Resources Group, LLC – Trademark Portfolio
Entity Type: 16
Biotech Resources Group, LLC holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include GMP IS IN OUR DNA, GMP IS IN OUR MRNA, and GMP IS IN OUR PDNA. The owner is based in Gaithersburg, MD.
505 Helene Street
Gaithersburg, MD 20878
Showing of trademarks Trademarks
Trademark Classifications
Biotech Resources Group, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does Biotech Resources Group, LLC have?
Biotech Resources Group, LLC has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 abandoned.
What trademark classes does Biotech Resources Group, LLC file in?
Biotech Resources Group, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 16 (Paper Goods). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Biotech Resources Group, LLC's most well-known trademarks?
Biotech Resources Group, LLC's registered trademark portfolio includes well-known marks such as GMP IS IN OUR DNA, GMP IS IN OUR MRNA, and GMP IS IN OUR PDNA. These are among 3 currently registered trademarks in the portfolio.
What is Biotech Resources Group, LLC's trademark registration success rate?
Biotech Resources Group, LLC has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.